We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Apothecus Pharmaceutical drew a warning letter from the FDA for quality and data integrity violations at its manufacturing facility in Hicksville, New York. Read More
The FDA’s Office of Prescription Drug Promotion hit Nascent Biotech with an untitled letter over claims on its website for the investigational brain cancer drug Pritumumab. Read More
The FDA hit a Rancho Cucamonga drug manufacturer with a warning letter for serious GMP violations at its facility including inadequate testing. Read More
Discount store chain Dollar Tree was hit with an FDA warning letter for receiving adulterated over-the-counter drug products from foreign drugmakers in hot water with the agency. Read More
The FDA cited an Eli Lilly facility in Puerto Rico, an Aurobindo plant in southern India and five other facilities for a wide range of GMP and other violations observed during inspections by agency officials. Read More
The FDA issued recent warning letters to manufacturing facilities in India, South Korea, China and the U.S., for a wide range of deficiencies, including inadequate testing. Read More
Indian drugmaker Cadila Healthcare was slapped with an FDA warning letter for serious violations at its injectable drug manufacturing facility in Ahmedabad, including cross-contamination from non-dedicated equipment. Read More
Italian API manufacturer Icrom was hit with a ten-item Form 483 by the FDA for serious quality violations at its facility in Concorezzo, north east of Milan. Read More
Mylan was hit with an FDA warning letter for serious GMP violations at an API manufacturing facility in Andhra Pradesh, India, including improper handling of raw materials. Read More